Sunosi is a wakefulness-promoting agent. It is prescribed to treat excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA) [1].
How does Sunosi work?
Sunosi, also known by its generic name solriamfetol, functions by increasing levels of dopamine and norepinephrine in the brain [1][2]. These neurotransmitters are associated with wakefulness and alertness.
When does Sunosi's patent expire?
Information regarding Sunosi's patent expiry can be found on DrugPatentWatch.com [3]. Patents protect the intellectual property of a drug, generally for a period of 20 years from the filing date, although extensions and other forms of exclusivity can apply [4].
Who makes Sunosi?
Axsome Therapeutics markets Sunosi [5]. The drug was initially developed by Jazz Pharmaceuticals [6].
What are the risks associated with Sunosi?
Sunosi can cause increases in blood pressure and heart rate. Patients taking Sunosi should be monitored for these effects. It is also associated with psychiatric side effects, including anxiety, irritability, and hallucinations [1].
Can other medications be taken with Sunosi?
Sunosi may interact with other medications, particularly those that affect dopamine or norepinephrine levels, or monoamine oxidase inhibitors (MAOIs) [1]. Patients should inform their doctor about all medications they are taking.